Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 11/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | FPR1 | P21462 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14903124 | 0.81 | FPR2 (1.00) | FPR2KMT2AMEN1RAB9ANPC1 | |
| SCHEMBL27981349 | 0.81 | KMT2A (0.59) | FPR2KMT2AMEN1RAB9ANPC1 | |
| SCHEMBL14889976 | 0.80 | FPR2 (0.73) | FPR2KMT2AMEN1RAB9ANPC1 | |
| SCHEMBL14902609 | 0.80 | FPR2 (0.65) | FPR2KMT2AMEN1RAB9ANPC1 | |
| SCHEMBL16588684 | 0.78 | FPR2 (0.70) | FPR2KMT2AMEN1RAB9ANPC1 | |
| SCHEMBL15312228 | 0.72 | FPR2 (0.72) | FPR2KMT2AMEN1RAB9ANPC1 | |
| SCHEMBL16738203 | 0.72 | FPR2 (0.72) | FPR2KMT2AMEN1RAB9ANPC1 | |
| SCHEMBL21239537 | 0.72 | FPR2 (0.77) | FPR2KMT2AMEN1RAB9ANPC1 | |
| SCHEMBL21239461 | 0.72 | FPR2 (0.77) | FPR2KMT2AMEN1RAB9ANPC1 | |
| SCHEMBL21239460 | 0.72 | FPR2 (0.77) | FPR2KMT2AMEN1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210008085-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN INC (US) | 2021-01-14 | — | — | US | disclosed |
| US-20210000846-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN INC (US) | 2021-01-07 | — | — | US | disclosed |
| US-10799518-B2 | Use of agonists of formyl peptide receptor 2 for treating dermatological diseases | ALLERGAN, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200246360-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN INC (US) | 2020-08-06 | — | — | US | disclosed |
| US-10208071-B2 | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases | ALLERGAN, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-9850264-B2 | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases | ALLERGAN, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170320897-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. | 2017-11-09 | — | — | US | disclosed |
| US-20140256684-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256685-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10799518-B2 | Use of agonists of formyl peptide receptor 2 for treating dermatological diseases | FPR2, FPR1, FPR3 | FPR2 1/4885KMT2A 4486/4885MEN1 4375/4885 |
| US-10208071-B2 | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases | FPR2, FPR1, FPR3 | FPR2 1/4885KMT2A 4567/4885MEN1 4240/4885 |
| US-20210008085-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885KMT2A 4486/4885MEN1 4375/4885 |
| US-20140256685-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885KMT2A 4486/4885MEN1 4375/4885 |
| US-20210000846-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885KMT2A 4486/4885MEN1 4375/4885 |
| US-20140256684-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885KMT2A 4567/4885MEN1 4240/4885 |
| US-20170320897-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885KMT2A 4567/4885MEN1 4240/4885 |
| US-20200246360-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885KMT2A 4486/4885MEN1 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.